Anika TherapeuticsvsJohnson & Johnson

ANIK and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ANIK

Anika Therapeutics Inc.

$13.28

Value $178M

+5.99%
ANIK's page

Anika Therapeutics (ANIK) has a market value of $178M and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, ANIK moved +41.1% and JNJ +39.7%. Dividend yield: ANIK none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ANIK$178M

    JNJ$644B

    JNJ is 3,618 times ANIK

  • Revenue, 12 months

    ANIK$123M

    JNJ$99.3B

    JNJ is 805 times ANIK

  • Net income, 12 months

    ANIK-$1.8M

    JNJ$16.1B

  • Operating margin

    ANIK-2.1%

    JNJ–

  • ROIC

    ANIK-1.5%

    JNJ12.4%

    13.9 points apart

  • P/E

    ANIK–

    JNJ40.0

  • Dividend yield

    ANIK0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    ANIK-65.8%

    JNJ+92.0%

    157.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ANIK-65.8%

JNJ+92.0%

5010015020020222023202420252026
Returns by period
PeriodANIKWith dividendsJNJWith dividends
1 year since November 17, 2025+41.1%Price +41.1%+39.7%Price +36.6%
3 years since November 17, 2023-35.1%-13.4% a yearPrice -35.1%+98.2%+25.6% a yearPrice +82.1%
5 years since November 17, 2021-65.8%-19.3% a yearPrice -65.8%+92.0%+13.9% a yearPrice +67.0%
10 years since November 21, 2016-70.4%-11.5% a yearPrice -70.4%+209.0%+11.9% a yearPrice +137.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ANIKAnika TherapeuticsJNJJohnson & Johnson

Valuation

ANIKJNJ
Valuation
Price$13.28$267.14
Market value$178M$644B
Enterprise value (EV)$133M$671B
P/E–40.0
P/E, 5-year median–21.9
P/B1.37.9
EV/EBIT–37.8
Free cash flow yield1.3%3.2%

Results and growth

ANIKJNJ
Results and growth
Revenue, 12 months$123M$99.3B
Net income, 12 months-$1.8M$16.1B
Free cash flow, 12 months$2.3M$20.6B
Earnings per share, 12 months-$0.13$6.59
Revenue growth, year on year-5.9%6.1%
Revenue growth a year, past-2.9%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ANIKJNJ
Margins and returns on capital
Gross margin63.4%67.6%
Operating margin-2.1%–
Net margin-1.4%16.2%
ROIC-1.5%12.4%
ROE-1.3%19.7%

Balance sheet

ANIKJNJ
Balance sheet
Cash$45M$17.2B
Total debt$26M$44.7B
Net debt / EBITDA-16.21.1
Interest cover–18.0×

Dividends and buybacks

ANIKJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield5.3%0.9%
Shareholder yield5.3%2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ANIK or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Anika Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 3,617.5 times Anika Therapeutics ($178M), at today's prices.

How did ANIK and JNJ stock do over the last 10 years?

Since November 21, 2016, ANIK's price moved -70.4% and JNJ's +137.1%. With dividends: ANIK -70.4% (-11.5% a year), JNJ +209.0% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ANIK or JNJ?

The dividend yield at today's price is none for Anika Therapeutics and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Anika Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was -1.4% for Anika Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -2.1% and –. Revenue was $123M and $99.3B.

Which is the better investment, Anika Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.